start portlet menu bar

Visualizador de conteúdo da Web

Display portlet menu
end portlet menu bar

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Página inicial Conhecimento Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.

Transferir este artigo

350 KB

Acerca deste artigo

Data

6 de set de 2016

Sumário

Vaccination with the commercial vaccine HIPRABOVIS® SOMNI/Lkt reduced the number of animals showing clinical respiratory signs and the number of concomitant treatments used during the first three months after arrival at the fattening farm.

Publicações relacionadas

Using HIPRABOVIS® SOMNI/LKT to control BRD in dairy calves: a field trial in Portugal Histophilus somni infection: an outbreak in cattle in Cental Italy Duration of immunity conferred after vaccination with HIPRABOVIS® SOMNI/LKT in young calves

Partilhar

start portlet menu bar

Vaccination against H. somni and M. haemolytica

Display portlet menu
end portlet menu bar

Consulte também

Publicações

Efficacy under field conditions of the new vaccine UBAC® in the reduction of Streptococcus...

10-07-2018
Post

Udder Health by HIPRA and CowSignals: 1 + 1 = 3

12-05-2017
Novidades

HIPRA presents UBAC®, the only specific vaccine against Strep. uberis

28-06-2018